8 completed, 6 recruiting, 3 unknown, 2 active not recruiting. 9 Phase 2, 3 Phase 3, 3 Phase 4, 2 Phase 1.
Follow Giant Cell Tumor of Bone: new trials by email Literature Review of Giant Cell Tumor of Bone trials Research Report on Giant Cell Tumor of Bone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery Indocyanine Green - Giant Cell Tumor of Bone | Phase 4 | Recruiting | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 40 | 2026-01-02 | 2026-01-05 |
| TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone Tartrate-Resistant Acid Phosphatase 5b - Giant Cell Tumor of Bone, TRACP-5b | Recruiting | St. Anne's University Hospital Brno, Czech Republic | 70 | 2026-01-01 | 2026-05-27 | |
| PROMIS and Mobility Evaluation in Sarcoma Patients Surgery - Sarcoma, Giant Cell Tumor of Bone | Recruiting | University of Calgary | 800 | 2025-07-01 | 2025-11-13 | |
| Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study ICG (Indocyanine Green) - Giant Cell Tumor of Bone | Phase 1 / Phase 2 | Recruiting | Tang Xiaodong | 45 | 2024-08-23 | 2024-10-18 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone XGEVA® - Giant Cell Tumor of Bone | Phase 4 | Active not recruiting | Amgen | 36 | 2023-08-17 | 2025-10-01 |
| A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Narlumosbart, Denosumab - Giant Cell Tumor of Bone | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 146 | 2023-04-01 | 2023-04-19 |
| Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage 4mg ZOL loaded gentamicin PMMA, gentamicin PMMA - Giant Cell Tumor of Bone | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 153 | 2023-03-01 | 2023-03-15 |
| A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone Denosumab - Giant Cell Tumor of Bone | Completed | Shanghai JMT-Bio Inc. | 301 | 2021-11-10 | 2022-06-02 | |
| The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand) - Spinal Tumor | Completed | Peking University Third Hospital | 100 | 2020-01-01 | 2021-07-07 | |
| Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Dietary Supplement: Calcium/Vitamin D - Giant Cell Tumor of Bone | Phase 1 / Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 139 | 2019-10-10 | 2022-10-14 |
| Reduced Dose-density of Denosumab for Unresectable GCTB Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] - Bone Giant Cell Tumor | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 2 | 2019-09-26 | 2021-01-06 |
| Giant Cell Tumor of the Bone in Young Patients Giant Cell Tumor of Bone | Completed | Istituto Ortopedico Rizzoli | 18 | 2019-06-05 | 2021-05-04 | |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone Zoledronic Acid - Giant Cell Tumor of Bone | Phase 3 | Recruiting | St. Louis University | 120 | 2018-05-03 | 2026-04-22 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China Denosumab - Giant Cell Tumor of Bone | Unknown | Peking University People's Hospital | 100 | 2018-03-01 | 2017-11-30 | |
| Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Denosumab - Giant Cell Tumor of Bone | Phase 4 | Completed | Amgen | 85 | 2017-11-13 | 2024-05-20 |
| Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone Denosumab - Giant Cell Tumor of Bone | Phase 3 | Unknown | Hebei Medical University Third Hospital | 30 | 2016-05-01 | 2017-08-24 |
| Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment curettage and resection - Giant Cell Tumor of Bone | Completed | Istituto Ortopedico Rizzoli | 412 | 2016-04-01 | 2016-12-22 | |
| Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Zoledronic acid - Giant Cell Tumor of Bone, Osteoclastoma | Phase 2 | Terminated | Leiden University Medical Center | 15 | 2008-12-01 | 2016-01-26 |
| Study of Denosumab in Subjects With Giant Cell Tumor of Bone Denosumab - Cancer, Giant Cell Tumors | Phase 2 | Completed | Amgen | 535 | 2008-09-09 | 2022-09-22 |
Showing 20 of 22. Sign in to see all of them.
Sarcoma (3) · Bone Neoplasms (2) · Giant Cell Tumors (2) · Alzheimer Disease (1) · Chondrosarcoma (1) · Chordoma (1) · Gastrointestinal Stromal Tumors (1) · Hemangiopericytoma (1) · Histiocytoma, Malignant Fibrous (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Recurrence (1)
Neoplasms by Histologic Type (22) · Neoplasms, Bone Tissue (22) · Neoplasms, Connective Tissue (22) · Neoplasms, Connective and Soft Tissue (22) · Neoplasms (21) · Giant Cell Tumors (20) · Neoplasms by Site (3) · Nervous System Diseases (3) · Bone Diseases (2) · Central Nervous System Diseases (2) · Musculoskeletal Diseases (2) · Neoplasms, Fibrous Tissue (2) · Nervous System Neoplasms (2) · Adnexal Diseases (1) · Brain Diseases (1)
Denosumab (10) · Indocyanine Green (2) · Vitamin D (2) · Zoledronic Acid (2) · Amputation, Surgical (1) · CTLA-4 Antigen (1) · Calcium (1) · Curettage (1) · Cyclophosphamide (1) · Dasatinib (1) · Ipilimumab (1) · Methods (1) · Nivolumab (1) · Surgical Procedures, Operative (1) · Transurethral Resection of Bladder (1)
Amgen (4) · Shanghai JMT-Bio Inc. (3) · Istituto Ortopedico Rizzoli (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hebei Medical University Third Hospital (1) · Leiden University Medical Center (1) · M.D. Anderson Cancer Center (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Sarcoma Alliance for Research through Collaboration (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Jiao Tong University Affiliated Sixth People's Hospital (1) · St. Anne's University Hospital Brno, Czech Republic (1) · St. Louis University (1) · Tang Xiaodong (1)
China (9) · United States (6) · Italy (4) · Canada (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Australia (2) · France (2) · Poland (2) · Sweden (2) · Austria (1) · Belgium (1) · Czechia (1) · Germany (1)
A H Taminiau, MD PhD (1) · Amir A Jazaeri (1) · Davide Donati, MD (1) · Emanuela Palmerini (1) · Guo Wei (1) · H Gelderblom, MD PhD (1) · Hans Gelderblom (1) · J R Kroep, MD PhD (1) · Michal Mahdal, M.D., Ph.D. (1) · N A Hamdy, MD PhD (1) · Ning Lang (1) · P C Hogendoorn, MD PhD (1) · P D Dijkstra, MD PhD (1) · S E Papapoulos, MD PhD (1)
PMID 41292259, PMID 17013643, PMID 21613624, PMID 25684041, PMID 27526293, PMID 29211870, PMID 30099641, PMID 30231890, PMID 31040253, PMID 31188797, PMID 32224746, PMID 33094400, PMID 33214476, PMID 33482769, PMID 33754215, PMID 37121582, PMID 37121591, PMID 37178368, PMID 3805057, PMID 39500883, PMID 4910256
2017 (1), 2018 (1)